213 related articles for article (PubMed ID: 36411577)
1. Bioactives from Marine Organisms and their Potential Role as Matrix Metalloproteinase Inhibitors.
Thomas NV; Monica Diyya AS; Kim SK; Faraj KA; Ghafoor DD; Qian ZJ; Tigabu BM
Curr Pharm Des; 2022; 28(41):3351-3362. PubMed ID: 36411577
[TBL] [Abstract][Full Text] [Related]
2. Metalloproteinase inhibitors: status and scope from marine organisms.
Thomas NV; Kim SK
Biochem Res Int; 2010; 2010():845975. PubMed ID: 21197102
[TBL] [Abstract][Full Text] [Related]
3. Potential matrix metalloproteinase inhibitors from edible marine algae: a review.
Thomas NV; Manivasagan P; Kim SK
Environ Toxicol Pharmacol; 2014 May; 37(3):1090-100. PubMed ID: 24780533
[TBL] [Abstract][Full Text] [Related]
4. Fucoidans from marine algae as potential matrix metalloproteinase inhibitors.
Thomas NV; Kim SK
Adv Food Nutr Res; 2014; 72():177-193. PubMed ID: 25081083
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects.
Zhang C; Kim SK
Mar Drugs; 2009 Mar; 7(2):71-84. PubMed ID: 19597572
[TBL] [Abstract][Full Text] [Related]
6. Marine pharmacology: therapeutic targeting of matrix metalloproteinases in neuroinflammation.
Gentile E; Liuzzi GM
Drug Discov Today; 2017 Feb; 22(2):299-313. PubMed ID: 27697495
[TBL] [Abstract][Full Text] [Related]
7. Phlorotannins and fucoidans from marine macroalgae as matrix metalloproteinase inhibitory substances and their possible application as medicinal foods.
Kim SK; Thomas NV; Li X
Adv Food Nutr Res; 2011; 64():129-41. PubMed ID: 22054943
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges.
Shi Y; Ma X; Fang G; Tian X; Ge C
NanoImpact; 2021 Jan; 21():100293. PubMed ID: 35559782
[TBL] [Abstract][Full Text] [Related]
9. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
Winer A; Adams S; Mignatti P
Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
Li W; Saji S; Sato F; Noda M; Toi M
Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase enzymes and their naturally derived inhibitors: novel targets in photocarcinoma therapy.
Gupta A; Kaur CD; Jangdey M; Saraf S
Ageing Res Rev; 2014 Jan; 13():65-74. PubMed ID: 24355347
[TBL] [Abstract][Full Text] [Related]
12. Progress in the development of matrix metalloproteinase inhibitors.
Tu G; Xu W; Huang H; Li S
Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
[TBL] [Abstract][Full Text] [Related]
13. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.
Lin H; Xu P; Huang M
Future Med Chem; 2022 Jan; 14(1):35-51. PubMed ID: 34779649
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
15. Hydroxamic acids as matrix metalloproteinase inhibitors.
Verma RP
Exp Suppl; 2012; 103():137-76. PubMed ID: 22642192
[TBL] [Abstract][Full Text] [Related]
16. The past, present and future perspectives of matrix metalloproteinase inhibitors.
Li K; Tay FR; Yiu CKY
Pharmacol Ther; 2020 Mar; 207():107465. PubMed ID: 31863819
[TBL] [Abstract][Full Text] [Related]
17. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
[TBL] [Abstract][Full Text] [Related]
18. The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches?
Koutroulis I; Zarros A; Theocharis S
Expert Opin Ther Targets; 2008 Dec; 12(12):1577-86. PubMed ID: 19007324
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).
Li X; Wu JF
Recent Pat Anticancer Drug Discov; 2010 Jun; 5(2):109-41. PubMed ID: 19951249
[TBL] [Abstract][Full Text] [Related]
20. Seesaw of matrix metalloproteinases (MMPs).
Kapoor C; Vaidya S; Wadhwan V; ; Kaur G; Pathak A
J Cancer Res Ther; 2016; 12(1):28-35. PubMed ID: 27072206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
